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SELF-REPORTED GENERAL HEALTH WAS THE MOST INFLUENTIAL 
VARIABLE OF EQ-5D SOCIAL PREFERENCES SCORES IN A GENERAL 
POPULATION SURVEY IN ARGENTINA, AND ITS INFLUENCE DIFFERED 
ACCORDING TO GENDER, AGE AND INCOME STATUS
Augustovski FA1, Irazola V1, Caporale JE1, Rubinstein A1, Kind P2
1Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2University of 
York, York, UK
OBJECTIVES: To evaluate the relationship of self reported general health [GH] on 
the EQ-5D preference scores (time trade-off [TTO]) as well as its independent inﬂuence 
when demographic, socioeconomic, and risk factors are included. METHODS: 41,392 
adults from the ﬁrst general population survey from a nationally representative sample 
were included: National Risk Factor [RF] Survey (2005). Variables included GH, 
sociodemographic parameters (SD) and RF (diabetes [DBT], high blood pressure 
[HBP], dyslipemia [DLP], obesity [OB], smoking [SMK], healthy diet [HD], physical 
activity [PA]), and the EQ-5D instrument. EQ-5D proﬁles were mapped to TTO 
preference values using a local EQ-5D Value study. We assessed the independent 
relationships between EQ-5D scores with GH, SD, and RF. We used multivariable 
linear regression modeling. RESULTS: Final models included 33,964 subjects 
(representing 17,586,759 subjects). Before including GH the following variables were 
statistically, consistently, and clinically associated with EQ-5D scores: age, gender, 
income, selected provinces, health coverage, DBT, HBP, DLP, PA, OB (R2 0.16). 
Nevertheless, when GH was incorporated, it showed to be the most important explan-
atory variable (R2 0.35) and most health variables lost their association (DBT, HBP, 
DLP, OB). Moreover, a signiﬁcant interaction was found in relation with age (50), 
gender and income. Although GH was still signiﬁcant in all the eight subgroups deﬁned 
by the three variables with positive interactions, the magnitude of the coefﬁcients 
corresponding with each category of GH signiﬁcantly varied (subgroup numbers 
ranged between 1501 and 8637, and R2 from 0.16 to 0.46). CONCLUSIONS: In 
Argentina, GH is the strongest parameter associated with scores on the EQ-5D. The 
magnitude of this association varied according to age, gender an income level. Based 
on these ﬁndings, we suggest that the inﬂuence of GH on individuals’ preferences 
should be evaluated by subgroup since its relevance seems to vary according to selected 
individual’s attributes.
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EFFECTS OF TADALAFIL ON HEALTH-RELATED QUALITY OF LIFE IN 
PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Pepke-Zaba J1, Beardsworth A2, Chan M3, Angalakuditi M4
1Papworth Hospital, Cambridge, CB3 8RE, UK, 2Eli Lilly and Company, Erl Wood, ELCL, UK, 
3Eli Lilly and Company, Danforth, Toronto, Canada, 4Eli Lilly and Company, Indianapolis, IN, 
USA
OBJECTIVES: Pulmonary arterial hypertension (PAH) is deﬁned as a chronic eleva-
tion of mean pulmonary arterial pressure above 25 mm HGg and pulmonary resis-
tance that can lead to right ventricular failure. Current PAH treatments reduce 
pulmonary vascular resistance. Tadalaﬁl causes vaso-dilatation and long term remod-
eling of the pulmonary arteries by inhibiting phosphodiesterase type 5 (PDE5). The 
effects of Tadalaﬁl on quality of life were assessed in patients with PAH. METHODS: 
A double-blind clinical trial randomized 405 patients with PAH treated with placebo 
or oral Tadalaﬁl at doses of 2.5, 10, 20, or 40 mg/d, most patients had idiopathic 
PAH, with symptoms in WHO functional class III. At baseline and 16 weeks, quality 
of life was assessed using the Short Form 36 (SF-36) and EuroQol 5D (EQ-5D). 
Change from baseline to week 16 in the SF-36 domains and EQ-5D measures index 
scores and visual analog scale (VAS)] were tested using ANCOVA controlling for 
baseline randomization factors of each dose compare to Placebo separately. RESULTS: 
All Tadalaﬁl groups had signiﬁcant improvement at 16 weeks in the Physical Function-
ing, Vitality, and Social Function domains of the SF-36. The Tadalaﬁl 40 mg/d group 
also had signiﬁcant improvement in the Role-Physical, Bodily Pain, and General 
Health domains compared with placebo (all P  0.01). For the EQ-5D, all Tadalaﬁl 
groups had signiﬁcantly greater utility index scores at 16 weeks, with the greatest 
improvement in the Tadalaﬁl 40 mg/d group (P  0.0001 from placebo). Only the 
Tadalaﬁl 40 mg/d group had an increase in VAS from baseline to 16 weeks compared 
with placebo (P  0.05). CONCLUSIONS: Patients with PAH treated for 16 weeks 
with Tadalaﬁl 40 mg/d had signiﬁcant improvements in their quality of life, as mea-
sured by the SF-36 and EQ-5D, compared with placebo.
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CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES 
CON RIESGO CARDIOVASCULAR
Alfonzo N, Bastardo YM
Central University of Venezuela, Caracas, Venezuela
OBJECTIVOS: Describir la calidad de vida relacionada con la salud (CVRS) de paci-
entes que asisten a un programa de atención farmacéutica para pacientes con riesgo 
cardiovascular (PAF_RCV) y explorar la asociación entre CVRS y factores de riesgo 
cardiovascular en dicha población. METODOLOGÍAS: Una muestra de conveniencia 
de 60 pacientes que asisten al PAF-RCV fueron entrevistados usando un cuestionario 
escrito. La CVRS fue determinada usando el Cuestionario de Salud SF-36 (SF-36 
Health Survey). Los datos acerca de factores de riesgo cardiovascular fueron extraídos 
de las historias clínicas. La asociación entre los componentes sumarios físico (CSF) y 
mental (CSM) del SF-36 y factores de riesgo cardiovascular fue estimada calculando 
coeﬁciente de correlación de Pearson para variables continuas y coeﬁciente T de 
Kendall para variables categóricas. RESULTADOS: La muestra estuvo formada de 29 
mujeres y 31 hombres con una edad promedio de 61.39 años (d.e. 10 años). Cuarenta 
y cinco sujetos (80.4%) tenían diagnóstico de hipertensión, 27 (48.2%) de diabetes y 
38 (63.35%) de dislipidemia. Todas las escalas del SF-36, excepto Función Social, 
mostraron una ﬁabilidad buena (A de Cronbach 0.7). Los valores obtenidos para las 
dimensiones del SF-36 fueron: Función Física  77.84, Rol Físico  77.78, Dolor 
Corporal  68.17, Salud General  74.57, Vitalidad  66.90, Función Social  77.92, 
Rol Emocional  82.18 y Salud Mental  80.67. El IMC, la Hg1Ac, y la PAS se 
encontraron estar negativamente asociadas con el CSF del SF-36. No se encontró 
asociación entre el CSM y los factores de riesgo cardiovascular. CONCLUSIONES: 
En general, la calidad de vida relacionada con la salud de los pacientes que asisten al 
PAF_RCV es buena. Este estudio demuestra asociación entre dimensiones físicas de 
la calidad de vida relacionada con la salud y ciertos factores de riesgo cardiovascular 
tales como valores elevados de presión arterial, hemoglobina glicosilada e índice de 
masa corporal.
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ANÁLISIS DEL CONSUMO DE AGENTES HIPOLIPEMIANTES EN 
COLOMBIA DEL 2002 AL 2006
Alfonso R1, Herran S2, Alfonso R3
1University of Washington, Seattle, WA, USA, 2Random Foundation, Bogotá, Colombia, 
3RANDOM Foundation, Bogota, Colombia
OBJECTIVOS: Describir el comportamiento del consumo de hipolipemiantes, en 
Colombia durante el período 2002–2006 METODOLOGÍAS: Princípios activos del 
grupo terapéutico C10A: “Reductores del colesterol y los triglicéridos” de la Clasiﬁ-
cación Internacional de la Organización Mundial de la Salud, Anatomical Therapeutic 
Chemical Association fueron seguidos a través de los reportes trimestrales de venta 
de IMS como medida indirecta de consumo; datos de suministro del medicamento o 
información directa de los pacientes no estaba disponible. RESULTADOS: Al inicio 
del estudio, estaban disponibles multiples presentaciones de hipolipemiantes: Resinas 
(n  6), ﬁbratos (n  96) y estatinas (n  220), incluyendo productos originales, 
genéricos y multifuente. En 2006, hubo un aumento en la cantidad de presentaciones 
disponibles: resinas (n  7), ﬁbratos (n  143) y estatinas (n  505). El consumo anual 
de hipolipemiantes aumento de 1,914,514 a 2,910,291 unidades, equivalentes a 
21,975,739 en Dosis Diaria Deﬁnida (DDD) en 2002 y 35,208,249 DDD en 2006; 
ajustando por la población en cada ano del seguimiento: 1.47 DDD por mil habitantes 
(DHD) y 2.21 DHD, ambos valores muy inferiores a los casi 18 DHD calculados a 
partir de la prevalencia de hipercolesterolemia en Colombia. Las estatinas tuvieron el 
mayor crecimiento pasando del 69.8% al 82.6% del total de los hipolipemiantes. La 
lovastatina fue el producto de mayor consumo y es la única incluida en el plan obliga-
torio de salud, alcanzando el 52.5% del total de unidades con una tendencia creciente 
permanente. Las estatinas disminuyeron su precio promedio casi en un 20% del valor 
inicial en el 2002 frente al 2006, lo que no sucedió con los ﬁbratos o las resinas 
que subieron de precio en ese mismo período en un 55% y 22% respectivamente. 
CONCLUSIONES: El consumo de hipolipemiantes, a expensas de las estatinas, ha 
aumentado, sin embargo su consumo sigue siendo inferior al calculado según la preva-
lencia de hipercolesterolemia en Colombia.
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EVALUATION OF THREE METHODS: OF SCHEDULING APPOINTMENT 
USING SIMULATION EXPERIMENTS
Sobolev B1, Sanchez V1, Kuramoto L2
1University of British Columbia, Vancouver, BC, Canada, 2Vancouver Coastal Health 
Research Institute, Vancouver, BC, Canada
OBJECTIVES: This study compared three methods of scheduling clinic appointments 
in a surgical service with several specialists: placing patients on the list of the referral 
surgeon (individual lists); placing patients on the list of the surgeon who has fewest 
patients waiting (shortest list); and placing patients on one list (pooled list). 
METHODS: A simulation study was used to estimate differences in clearance times 
and weekly appointment rates across scheduling methods. We used a discrete-event 
simulation model to represent the progress of patients through steps of the process of 
surgical care. We conducted the simulation experiments using group randomized 
design, in which the unit of allocation was the hospital and the units of analysis were 
the hospital and the patient. The outcome measures were clearance time for hospitals 
and time to appointment for patients. RESULTS: Clearance times were more than 1.5 
weeks longer in hospitals using individual lists (adjusted difference  1.6 weeks, 95% 
CI 1.4–1.8) and shortest lists (adjusted difference  1.7 weeks, 95% CI 1.5–1.9) 
scheduling methods as compared to pooled lists. After adjustment for hospital and 
patient factors, the weekly likelihood that patients on the appointment list had their 
consultation with a surgeon was 78% lower for individual lists (adjusted OR  0.22, 
95% CI 0.21–0.22) and shortest lists (adjusted OR  0.22, 95% CI 0.22–0.23) as 
compared to pooled lists. CONCLUSIONS: Our analysis suggests that clearance times 
were shorter in hospitals where patients wait in a single queue and that each week a 
larger proportion of patients were likely to have an appointment if they were in a 
single queue.
